Pricing Log in Create free account

BeyondSpring Inc. (BYSI) vs TransCode Therapeutics Inc. (RNAZ)

BeyondSpring Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. BeyondSpring Inc. and TransCode Therapeutics Inc. are of similar size ($26.0M and $25.6M). Across the 8 metrics below, BeyondSpring Inc. leads on 4 and TransCode Therapeutics Inc. on 4.

Valuation

Metric BYSI RNAZ Biotechnology median
P/E n/m n/m 10.60
P/S 18.57 n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.11 0.66
EV/Sales 15.37 n/m 9.02
Earnings yield (28.28%) (3,354.19%) (32.88%)
Free cash flow yield (66.96%) (1,565.69%) (23.13%)

Profitability

Metric BYSI RNAZ Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 24.96% 429.61% (51.96%)
Return on assets (29.29%) (58.12%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BYSI RNAZ Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 92.86% 96.02% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BYSI RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.70 1.97 4.97
Net debt to EBITDA 1.42 0.64 1.01

Dividend

Metric BYSI RNAZ Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BYSI RNAZ Biotechnology median
Market cap 26.00m 25.57m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack